publication venue for
- The AML1/ETO target gene WBSCR5 (NTAL/LAB) is regulated during myeloid differentiation 2006
- Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry.. 1-8. 2024
- Transfusion of blood components in pediatric age groups: an evidence-based clinical practice guideline adapted for the use in Egypt using ‘Adapted ADAPTE’. 103:1373-1388. 2024
- The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. 101:1023-1030. 2022
- Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. 100:1917-1918. 2021
- Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. 100:1181-1194. 2021
- Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the “real world”. 100:1261-1266. 2021
- Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. 99:2689-2698. 2020
- R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. 99:105-112. 2020
- Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. 98:2035-2044. 2019
- Correction to: Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. 97:2531-2531. 2018
- Comparison of argatroban and fondaparinux for the management of patients with isolated heparin-induced thrombocytopenia. 97:2055-2059. 2018
- Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. 97:1889-1901. 2018
- A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry. 96:2025-2029. 2017
- Is low serum albumin level a significant predictor for the development of heparin-induced thrombocytopenia-thrombosis?. 96:1033-1036. 2017
- Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia. 95:1023-1025. 2016
- Refractory mixed autoimmune hemolysis, thrombocytopenia, and thrombosis: a diagnostic puzzle. 94:1055-1056. 2015
- The Canadian Choosing Wisely campaign: the Canadian Hematology Society’s top five tests and treatments. 94:541-545. 2015
- Mutations in the paralogous human α-globin genes yielding identical hemoglobin variants. 88:535-543. 2009
- 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. 88:485-490. 2009
- The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review. 87:961-973. 2008
- Treatment Strategies in Elderly Patients with Aggressive Histology Lymphoma. 80:B86-B88. 2001
- Serology versus ARMS-PCR in prospective HLA-class I typing for bone marrow transplantation. 77:97-100. 1998
- Effects of factor VIII concentrates on the immune system in hemophilic patients. 63:145-151. 1991